Gene therapy of human ovarian carcinoma in vitro
10.3969/j.issn.1000-8179.20140756
- VernacularTitle:融合基因CDglyES重组腺病毒对卵巢癌细胞抑制作用的体外研究
- Author:
Pu LI
;
Dongtian LI
;
Bingnan YIN
;
Hua TANG
;
Lirong YIN
- Publication Type:Journal Article
- Keywords:
human ovarian cancer;
cytidine deaminase;
endostadine;
adenovirus;
gene therapy
- From:
Chinese Journal of Clinical Oncology
2014;(13):861-865
- CountryChina
- Language:Chinese
-
Abstract:
To construct a recombinant adenovirus containing CDglyES fusion gene, which can directly inhibit human ovarian cancer cell and indirectly inhibit vascular endothelial cell growth. Methods:We constructed prAdCDglyES using a homolo-gous recombination method in bacteria. The prAdCDglyES was transfected to 293 packaging cells using liposome, in which rAdCDgly-ES was packaged and amplified. MTT was used to observe the proliferation inhibition effect of rAdCDglyES on human ovarian cancer cells and the growth inhibition effect of expressing products of rAdCDglyES on ECV-304. Results:The titer of rAdCDglyES was 1 × 1013.3 TCID50/L, whereas the inhibition rate on human ovarian cancer cell SKOV-3 was (83.1±6.3)%. This result is significantly different from the control rAd-LacZ, which had an inhibition rate of (24.1 ± 13.2)% (P<0.01). The concentrated culture supernatant from cells transfected with rAdCDglyES can inhibit ECV-304 cell proliferation at a rate of (78.7 ± 1.6)%. This rate is significantly different com-pared with that of the control with the same concentration of culture supernatant from cells transfected with rAd-CD, with an effect on ECV-304 cell shown by an inhibition rate of (23.9 ± 9.7)%(P<0.01). Conclusion:The results showed that the recombinant adenovirus rAdCDglyES could inhibit human ovarian cancer cells directly and indirectly.
